Various malaria vaccine candidate antigens are in different stages of clinical trials, of which circumsporozoite protein (CSP) antigen-based RTS,S vaccine is under phase-3 trial and the results have showed moderate efficacy against both clinical and severe malaria among the young infants [28]. The gene discussed is DNAJC5; the disease is malaria.